Andere Sprachen Bayer AG

Aktien

BAY001

DE000BAY0017

BAYN

Pharmazeutika

Realtime-Estimate Tradegate Andere Börsenplätze 10:10:29 21.05.2026			% 5 Tage	Veränd. 1. Jan.
38,95 ^EUR	-0,71 %		+1,78 %	+5,00 %

08:46	FDA beschleunigt Prüfung von zusätzlicher Finerenon-Indikation	DJ
08:34	Bayer: FDA gewährt vorrangiges Prüfverfahren für Finerenon	RE

Andere Sprachen

10:06	Can Bayer Still Recover?
08:34	Bayer says FDA grants priority review designation for finerenone
08:31	Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease
20.05.	¿Hay alguna cura para Bayer?
20.05.	Bayer peut-il encore guérir ?
19.05.	Nvidia: ¿lo logrará otra vez?
19.05.	Can Nvidia Do It Again?
19.05.	Bayer annonce de bonnes nouvelles pour son produit Asundexian
19.05.	Bayer's New Drug Application for Stroke Prevention Treatment Secures US, Japanese Nods
19.05.	Bourse : ArcelorMittal vend des actions Vallourec, Safran et Vinci à l'achat
19.05.	Morning Meeting: La bolsa sigue acusando la amenaza de subidas de tipos
19.05.	Bayer: U.S. FDA grants priority review for asundexian in patients after ischaemic strokes
19.05.	Bayer : New drug applications for asundexian accepted by U.S. Food and Drug Administration under Priority Review and by Japan’s Ministry of Health, Labour and Welfare
19.05.	Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
19.05.	Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After A Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack
19.05.	The stock market still recoils at the prospect of higher rates
19.05.	Les valeurs à suivre à Paris et en Europe (actualisé)
18.05.	Bayer agrees to pay $133 million for PCB cleanup in two states
18.05.	U.S. FDA grants priority review to supplemental new drug application for Hyrnuo® (sevabertinib)
18.05.	U.S. FDA Grants Priority Review to Supplemental New Drug Application for HYRNUO® (sevabertinib) Under Investigation as a First-Line Treatment of HER2-Mutated Non-Small Cell Lung Cancer
18.05.	Bayer Receives U.S. FDA Priority Review For Hyrnuo As First-Line Treatment Of Her2-Mutated Non-Small Cell Lung Cancer
18.05.	Bayer - FDA priority review for sevabertinib
18.05.	Bayer : FDA grants sevabertinib Priority Review as a first-line treatment for patients with HER2-mutant non-small cell lung cancer
15.05.	AUA 2026: Phase II ARASEC Data Further Supports the Efficacy and Safety of NUBEQA® (darolutamide) Plus ADT in Patients with Metastatic Castration-Sensitive Prostate Cancer
15.05.	Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement